Scientific article
Open access

Drug Pricing Evolution in Hepatitis C

Published inPloS one, vol. 11, no. 6, e0157098
Publication date2016

We aimed to determine the association between the stepwise increase in the sustained viral response (SVR) and Swiss and United States (US) market prices of drug regimens for treatment-naive, genotype 1 chronic hepatitis C virus (HCV) infection in the last 25 years. We identified the following five steps in the development of HCV treatment regimens: 1) interferon (IFN)-α monotherapy in the early '90s, 2) IFN-α in combination with ribavirin (RBV), 3) pegylated (peg) IFN-α in combination with RBV, 4) the first direct acting antivirals (DAAs) (telaprevir and boceprevir) in combination with pegIFN-α and RBV, and 5) newer DAA-based regimens, such as sofosbuvir (which is or is not combined with ledipasvir) and fixed-dose combination of ritonavir-boosted paritaprevir and ombitasvir in combination with dasabuvir.

Citation (ISO format)
VERNAZ-HEGI, Nathalie et al. Drug Pricing Evolution in Hepatitis C. In: PloS one, 2016, vol. 11, n° 6, p. e0157098. doi: 10.1371/journal.pone.0157098
Main files (1)
Article (Published version)
ISSN of the journal1932-6203

Technical informations

Creation06/23/2016 9:03:00 AM
First validation06/23/2016 9:03:00 AM
Update time03/15/2023 12:29:54 AM
Status update03/15/2023 12:29:54 AM
Last indexation02/12/2024 11:25:07 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack